Approximately 2,100 subjects will be randomized in a 1:1:1 ratio to receive either rivaroxaban 15 mg once daily plus clopidogrel 75 mg daily for 12 months ( a WOEST trial-like strategy ) , or rivaroxaban 2.5 mg twice daily ( with stratification to a prespecified duration of DAPT 1 , 6 , or 12 months , an ATLAS trial-like strategy ) , or dose-adjusted VKA once daily ( with stratification to a prespecified duration of DAPT 1 , 6 , or 12 months , traditional triple therapy ) .